Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cohen

Showing results (951-960 of 1,023) with videos related to

Pageof 103
Sort By:
Nature Communications|December 6, 2019
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4Zhiyong Wang, Victoria H Wu, Michael M Allevato, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialP M Clement, T Gauler, J P Machiels, et al.
Science Translational Medicine|February 28, 2024
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancerAaron M Miller, Zeynep Koşaloğlu-Yalçın, Luise Westernberg, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individualEmilie Seydoux, Leah J Homad, Anna J MacCamy, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Nature Communications|June 9, 2023
Persistent serum protein signatures define an inflammatory subcategory of long COVIDAarthi Talla, Suhas V Vasaikar, Gregory Lee Szeto, et al.
Pageof 103

Showing results (951-960 of 1,023) with videos related to

Sort By:
Pageof 103
Nature Communications|December 6, 2019
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4Zhiyong Wang, Victoria H Wu, Michael M Allevato, et al.
Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialP M Clement, T Gauler, J P Machiels, et al.
Science Translational Medicine|February 28, 2024
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancerAaron M Miller, Zeynep Koşaloğlu-Yalçın, Luise Westernberg, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individualEmilie Seydoux, Leah J Homad, Anna J MacCamy, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Nature Communications|June 9, 2023
Persistent serum protein signatures define an inflammatory subcategory of long COVIDAarthi Talla, Suhas V Vasaikar, Gregory Lee Szeto, et al.
Pageof 103